Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
October 17 2023 - 6:22AM
Company Announcement
- Net sales of DARZALEX®
in the third quarter of 2023 totaled USD 2,499
million
- Genmab receives royalties on worldwide net sales from
Janssen Biotech, Inc. (Janssen)
COPENHAGEN, Denmark; October 17, 2023 –
Genmab A/S (Nasdaq: GMAB) announced today
that worldwide net trade sales of
DARZALEX® (daratumumab),
including sales of the subcutaneous (SC) product
(daratumumab and
hyaluronidase-fihj, sold under the tradename
DARZALEX FASPRO®
in the U.S.),
as reported by Johnson & Johnson were USD 2,499 million
in the third quarter of 2023. Net trade sales were USD
1,369 million in the U.S. and USD 1,130 million in the rest of the
world. Genmab receives royalties on the worldwide net sales of
DARZALEX, both the intravenous and SC products, under the exclusive
worldwide license to Janssen to develop, manufacture and
commercialize daratumumab.
About Genmab Genmab is an international
biotechnology company with a core purpose guiding its unstoppable
team to strive towards improving the lives of patients through
innovative and differentiated antibody therapeutics. For more than
20 years, its passionate, innovative and collaborative team has
invented next-generation antibody technology platforms and
leveraged translational research and data sciences, which has
resulted in a proprietary pipeline including bispecific T-cell
engagers, next-generation immune checkpoint modulators, effector
function enhanced antibodies and antibody-drug conjugates. To help
develop and deliver novel antibody therapies to patients, Genmab
has formed 20+ strategic partnerships with biotechnology and
pharmaceutical companies. By 2030, Genmab’s vision is to transform
the lives of people with cancer and other serious diseases with
Knock-Your-Socks-Off (KYSO™) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen,
Denmark with locations in Utrecht, the Netherlands, Princeton, New
Jersey, U.S. and Tokyo, Japan. For more information, please visit
Genmab.com and follow us on Twitter.com/Genmab.
Contact: Marisol
Peron, Senior Vice President, Global Communications & Corporate
AffairsT: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor RelationsT: +45
3377 9558; E: acn@genmab.com This Company Announcement contains
forward looking statements. The words “believe”, “expect”,
“anticipate”, “intend” and “plan” and similar expressions identify
forward looking statements. Actual results or performance may
differ materially from any future results or performance expressed
or implied by such statements. The important factors that could
cause our actual results or performance to differ materially
include, among others, risks associated with pre-clinical and
clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety
issues, uncertainties related to product manufacturing, the lack of
market acceptance of our products, our inability to manage growth,
the competitive environment in relation to our business area and
markets, our inability to attract and retain suitably qualified
personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated
entities, changes and developments in technology which may render
our products or technologies obsolete, and other factors. For a
further discussion of these risks, please refer to the risk
management sections in Genmab’s most recent financial reports,
which are available on www.genmab.com and the risk factors included
in Genmab’s most recent Annual Report on Form 20-F and other
filings with the U.S. Securities and Exchange Commission (SEC),
which are available at www.sec.gov. Genmab does not undertake any
obligation to update or revise forward looking statements in this
Company Announcement nor to confirm such statements to reflect
subsequent events or circumstances after the date made or in
relation to actual results, unless required by law. Genmab A/S
and/or its subsidiaries own the following trademarks: Genmab®; the
Y-shaped Genmab logo®; Genmab in combination with the Y-shaped
Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect®
and KYSO™. DARZALEX® and DARZALEX FASPRO® are trademarks of Johnson
& Johnson.
Company Announcement no. 43 CVR no. 2102 3884 LEI Code
529900MTJPDPE4MHJ122
Genmab A/SCarl Jacobsens Vej 302500 Valby Denmark
- 101723_CA43_DARZALEX Q3 Sales
Gen Digital (NASDAQ:GEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gen Digital (NASDAQ:GEN)
Historical Stock Chart
From Apr 2023 to Apr 2024